Quick Answer
Roivant Sciences Ltd. reported Long Term Debt of $430.59 million for the year ending 2024.
- Roivant Sciences Ltd. showed an increase of +14.7% in Long Term Debt from 2023 to 2024.
- This data is from Roivant Sciences Ltd.'s annual report (Form 10-K), filed with the SEC on May 30, 2024.
- XBRL data for this metric is available from 2021 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $186.35 million | Q3 2021: $199.87 million | Q4 2021: $204.04 million | Q2 2022: $383.72 million | Q3 2022: $376.06 million | Q4 2022: $375.12 million | Q2 2023: $385.07 million | Q3 2023: $389.45 million | Q4 2023: $403.34 million | Q1 2024: $430.59 million | Q2 2024: $311.72 million.
- Over the full 5 years of available data (2021 to 2024), Roivant Sciences Ltd.'s Long Term Debt has grown by 152.9%.
- Historical annual values: Fiscal year 2024: $430.59 million | Fiscal year 2023: $375.52 million | Fiscal year 2022: $210.03 million | Fiscal year 2022: $210.03 million | Fiscal year 2021: $170.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: